Equillium, Inc.(EQ)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,900 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
EQ Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Equillium, Inc. (EQ), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EQ at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,900 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.6) and balance sheet strength (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Equillium, Inc. reports net income of $-4.7M, free cash flow of $-4.2M. Top institutional holders of EQ by reported 13-F value include Jupiter Topco, Decheng Capital, Affinity Asset Advisors, based on the most recent SEC filings. EQ trades on the Nasdaq exchange and files with the SEC under CIK 1746466. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EQ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Equillium, Inc. directly from SEC EDGAR. Equillium, Inc.'s 13F Pro composite quality score has ranged between 11 and 32 since 2024, currently 11.7 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-4.7M
Free Cash Flow
Q2 2026
$-4.2M
ROIC
Q2 2026
-36.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-177.6% YoYOperating Income
-185.8% YoYEPS (Diluted)
-69.6% YoYTotal Assets
+24.5% YoYTotal Debt
Op. Cash Flow
-19.6% YoYFree Cash Flow
-19.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $41.1M +13.9% | $36.1M +129.0% | $15.8M | — | — |
| Net Income | $-22.4M -177.6% | $-8.1M +39.5% | $-13.3M +78.6% | $-62.4M -59.9% | $-39.1M -31.0% | $-29.8M |
| Operating Income | $-23.6M -185.8% | $-8.3M +43.1% | $-14.5M +76.6% | $-62.1M -64.3% | $-37.8M -27.9% | $-29.5M |
| EPS (Diluted) | $-0.39 -69.6% | $-0.23 +39.5% | $-0.38 +79.5% | $-1.85 -36.0% | $-1.36 | — |
| Total Assets | $31.9M +24.5% | $25.6M -49.3% | $50.5M -35.6% | $78.4M -8.2% | $85.4M -0.0% | $85.4M |
| Total Debt | — | — | — | $14.8M +27.4% | $11.6M -0.0% | $11.6M |
| Operating Cash Flow | $-22.7M -19.6% | $-19.0M +12.7% | $-21.8M -149.4% | $-8.7M +72.8% | $-32.1M -30.3% | $-24.6M |
| Free Cash Flow | $-22.8M -19.3% | $-19.1M +12.5% | $-21.8M -142.3% | $-9.0M +72.0% | $-32.1M -29.5% | $-24.8M |
Get alerted when EQ's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Equillium, Inc. including:
Top Institutional Holders of EQ
Jupiter Topco LLC
$20.7M6,494,571 shDecheng Capital LLC
$14.2M4,447,308 shAffinity Asset Advisors, LLC
$13.1M4,100,000 shADAR1 Capital Management, LLC
$12.0M3,758,569 shabrdn plc
$11.6M3,631,659 shWoodline Partners LP
$11.2M3,500,901 shRA CAPITAL MANAGEMENT, L.P.
$9.9M3,096,336 shStemPoint Capital LP
$6.5M2,016,607 shVANGUARD CAPITAL MANAGEMENT LLC
$5.8M1,822,812 shEversept Partners, LP
$4.9M1,520,824 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $20.7M | 6,494,571 |
| Decheng Capital LLC | $14.2M | 4,447,308 |
| Affinity Asset Advisors, LLC | $13.1M | 4,100,000 |
| ADAR1 Capital Management, LLC | $12.0M | 3,758,569 |
| abrdn plc | $11.6M | 3,631,659 |
| Woodline Partners LP | $11.2M | 3,500,901 |
| RA CAPITAL MANAGEMENT, L.P. | $9.9M | 3,096,336 |
| StemPoint Capital LP | $6.5M | 2,016,607 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.8M | 1,822,812 |
| Eversept Partners, LP | $4.9M | 1,520,824 |
Companies Similar to EQ
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NewAmsterdam Pharma Co N.V.
Arcus Biosciences, Inc.
Pelthos Therapeutics Inc.
Voyager Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Alector, Inc.
Taysha Gene Therapies, Inc.
uniQure N.V.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put EQ on your watchlist
Track score changes the day Equillium, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EQ a good stock to buy?
13F Pro's AI-powered analysis of Equillium, Inc. (EQ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EQ are available on the EQ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EQ is classified as a small company.
Which hedge funds own EQ?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EQ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Equillium, Inc.'s investment landscape.